Navigation Links
Bronchiectasis in Medical News

Transave Completes Enrollment in Arikace(TM) Phase II Bronchiectasis Study

Presently No Approved Treatments MONMOUTH JUNCTION, N.J., April 21 /PRNewswire/ -- Transave, Inc., today reported completion of patient enrollment in a Phase II study evaluating the safety and efficacy of Arikace(TM) (liposomal amikacin for inhalation) in non-cystic fibrosis (CF) bronchiect...

Pharmaxis to Expand Manufacturing Capacity

...eloping Bronchitol for the treatment of diseases including cystic fibrosis, bronchiectasis and chronic bronchitis. Construction of the key manufacturing equipment co...clude: Aridol for the management of asthma, Bronchitol for cystic fibrosis, bronchiectasis and chronic obstructive pulmonary disease (COPD) and PXS64 for the treatmen...

Arsenic in Drinking Water Predisposes Children To Lung Cancer in Later Life

...life. It was found that the risk of dying from bronchiectasis was 46 times more than normal if the child's mothe... than in the rest of Chile. The risk of death from bronchiectasis was 46 times greater. "In all my career, these are... these the highest death rates for lung cancer and bronchiectasis ever discovered among young adults, but they are a...
Bronchiectasis in Medical Technology

12 Month Phase 3 Trial Finds Bronchitol Safe in Bronchiectasis

SYDNEY, Australia, Aug. 20 /Xinhua-PRNewswire-FirstCall/ -- Pharmaceutical company Pharmaxis (ASX: PXS; Nasdaq: PXSL) today announced that the Phase 3 clinical trial evaluating the long term safety of Bronchitol in subjects with bronchiectasis has concluded with no serious adverse events attri...

Transave Receives $2.2 Million Cystic Fibrosis Foundation Award for Development of ARIKACE(TM)

...lung infections in cystic fibrosis (CF) and non-CF bronchiectasis patients. Transave announced today that the award...uated in the treatment of non-CF patients who have bronchiectasis with Pseudomonas lung infections. In the bronchiectasis trial, 64 adult patients were randomized 2:1 to tw...

Pharmaxis Announces Positive Results of Phase 3 Cystic Fibrosis Trial

...ic respiratory and immune disorders. Its development pipeline of products includes Aridol for the diagnosis of asthma, Bronchitol for cystic fibrosis, bronchiectasis and chronic obstructive pulmonary disease (COPD), PXS25 for the treatment of lung fibrosis and PXS4159 for asthma. Founded in 1998, Pharmaxis is liste...

Pharmaxis Announces New Drug Application Submission for Aridol(TM)

...c respiratory and immune disorders. Its development pipeline of products includes Aridol for the management of asthma, Bronchitol for cystic fibrosis, bronchiectasis and chronic obstructive pulmonary disease (COPD), PXS25 for the treatment of lung fibrosis and PXS4159 for asthma. Founded in 1998, Pharmaxis is ...

ASX/NASDAQ Media Release: Pharmaxis Files First Marketing Application for Bronchitol in Australia

...at more than 600,000 people in the major pharmaceutical markets suffer from bronchiectasis and Pharmaxis expects Bronchitol to be the first targeted medication for th...l need. In Australia, it is believed that more than 18,000 people live with bronchiectasis and over 70% are moderately or severely incapacitated by their condition. ...

Second Pivotal Phase 3 Trial In Cystic Fibrosis Begins

...4_CF302_Commences.pdf . Pharmaxis is developing Bronchitol as a treatment to improve mucus clearance in the lungs of patients with cystic fibrosis, bronchiectasis and chronic obstructive airway diseases. Bronchitol is a patented, inhalable dry powder formulation of mannitol that can be administered by a convenie...

Pharmaxis Concludes Special Protocol Assessment with FDA for Bronchitol Phase 3 Trial

...n the phase 3 registration trial of Bronchitol for bronchiectasis via the Special Protocol Assessment process. The...h internationally renowned experts in the field of bronchiectasis and will be a randomized, placebo controlled, doub...Phase III study to be undertaken for Bronchitol in bronchiectasis and follows the completion of a successful shorter...

Pharmaxis Long-Term Safety Study of Bronchitol Completes

...ting the safety of Bronchitol in 100 subjects with bronchiectasis has completed. This 12-month treatment period wa...le in the major pharmaceutical markets suffer from bronchiectasis and Pharmaxis expects Bronchitol to be the first t...tal U.S. medical care expenditure is US$13,000 per bronchiectasis patient, double that of patients without the disor...
Bronchiectasis in Medical Definition

Pathology

...r abscess - Vocal fold nodule - Laryngospasm Chronic lower respiratory diseases Emphysema - COPD - Asthma - Status asthmaticus - bronchiectasis Lung diseases due to external agents Coalworker's pneumoconiosis - Pneumoconiosis - Silicosis - Bauxite fibrosis - Berylliosis - S...
Bronchiectasis in Medical Dictionary

Bronchiectasis

Bronchiectasis is a disease that causes localized, irreversible dilation of part of the bronchial tree. It is classified as an obstructive lung disease, along with bronchitis and cystic fibrosis. Involved bronchi are dilated,... Bronchiectasis is an irreversible widening (dilation) ...

Respiratory disorders

...om leading medical centers. ... Welcome to the Respiratory Disorders Forum ... Respiratory Disorders / COPD / Occupational Lung Diseases / bronchiectasis ... While usually classified as a respiratory disorder , it is the pancreas which is ... Exclusive directory of alternative medicine, holisti...

Lung infection

...ncluding treatment and ... Infections . Kidney and Urinary Tract Disorders. Liver and ... in the course of lung infections help to prevent bronchiectasis or reduce its severity. ... Although CMV infection is usually harmless, it can cause severe disease in ... symptoms do appear, they include ...
Bronchiectasis in Biological Technology

Regulatory Path for Bronchitol in Bronchiectasis

SYDNEY, Australia, May 1 /Xinhua-PRNewswire-FirstCall/ -- Pharmaxis (AXS: PSX; Nasdaq: PXSL) today announced that it has agreed with advice from the U.S. Food and Drug Administration (FDA) on the design of a pivotal Phase 3 trial of the company's mucus clearing agent, Bronchitol, in patients w...

Transave Enters Into Cooperative Research Agreement With NIH To Study ARIKACE(TM) In Nontuberculous Mycobacteria

...letion of enrollment in two additional Phase II trials including a study where ARIKACE is being evaluated in the treatment of non-CF patients who have bronchiectasis with Pseudomonas lung infections and a second trial in U.S. CF patients with Pseudomonas lung infections. ARIKACE has been granted orph...

Pharmaxis Builds Senior Management Team

...c respiratory and immune disorders. Its development pipeline of products includes Aridol for the management of asthma, Bronchitol for cystic fibrosis, bronchiectasis and chronic obstructive pulmonary disease (COPD), PXS25 for the treatment of lung fibrosis and PXS4159 for asthma. Founded in 1998, Pharmaxis is liste...

Chronic Lung Disease - Axentis Pharma Attracts Investment Interest

...domonas aeruginosa. Chronic inflammations then cause lung functions to become blocked. In addition to the breakdown of lung tissue, this also leads to bronchiectasis and lung failure. For further information, please contact: Axentis Pharma AG Limmatquai 138 8001 Zurich Switzerland T: +4...

Pharmaxis Research Programs Highlighted at European Respiratory Society Congress

...nfectious lung diseases including tuberculosis -- A randomized, placebo-controlled trial of inhaled mannitol(Bronchitol) in patients with bronchiectasis -- Cough and airway hyperresponsiveness -- A comparison of inhaled mannitol (Aridol), methacholine provocation and eucapnic voluntary h...

Transave, Inc. Secures $12.5 Million in New Financing

...linical trial in a second area of high unmet need: bronchiectasis patients who have pseudomonas lung infections." ...tions in patients with non-cystic fibrosis-related bronchiectasis in Europe and India. The U.S. Food and Drug Admini...plans to expand this trial into the United States. bronchiectasis is the permanent widening of the bronchi (the larg...

Transave, Inc. Raises $35 Million Through Series D Convertible Preferred Stock Financing

...are on track to have Arikace Phase II clinical data in cystic fibrosis patients that have Pseudomonas lung infections this year. In addition, Phase II bronchiectasis data will be available in the first half of 2009," said Tim Whitten, President and Chief Executive Officer of Transave. Tim Whitten further commente...

Pharmaxis' First Steps into China

...clinical trial application for Bronchitol to treat bronchiectasis has been accepted for evaluation by China's State ...dicates that the number of Chinese who suffer from bronchiectasis is more than double that in the rest of the world....ory physicians have indicated they wish to conduct bronchiectasis studies, and have confirmed there is a large unmet...

Pharmaxis to Apply to Market Bronchitol in Australia

...rtson. "More than 20,000 Australians suffer from bronchiectasis and Pharmaxis expects Bronchitol to be the first t... years -- addressing an important medical need." bronchiectasis is an incurable, degenerative and chronic lung con...tal U.S. medical care expenditure is US$13,000 per bronchiectasis patient, double that of patients without the disor...

Pharmaxis Closes Share Purchase Plan

...c respiratory and immune disorders. Its development pipeline of products include, Aridol for the management of asthma, Bronchitol for cystic fibrosis, bronchiectasis and chronic obstructive pulmonary disease (COPD) and PXS64 for the treatment of multiple sclerosis. Founded in 1998, Pharmaxis is listed on the Austr...
Other Tags
(Date:2/28/2015)... February 28, 2015 The MCA Youth ... Malaysia into one platform and gears towards the goal ... A series of group talks in smaller groups will ... Building, Education, Personal Development, Leadership, Entrepreneurship, Healthcare, Social and ... awareness of Malaysian youths. , Young adults ...
(Date:2/28/2015)... Gerald “Solutionman” Haman surveyed over 10,000 ... to innovative thinking. “The #1 block was lack ... tools,” reports Haman, who created the Thinkubator Innovation Studio ... felt that they did not have enough time for ... to stimulate innovation. , Solutionman’s monthly “Accelerating Innovation Training” ...
(Date:2/28/2015)... 2015 March—also known as National ... remind ourselves and others that suspected head injuries, ... Specialists (ANS). , Concussions are a form of ... of TBIs. There are 1.6-3.8 million sports-related concussions ... but it is a brain injury. Many athletes ...
(Date:2/28/2015)... A study out of the University of ... for the treatment of a hereditary ocular condition that ... by Dr. Robert MacLaren, professor of ophthalmology at the ... Journal on January 16, 2014 , the study treated ... that mostly affects men and leads to the degeneration ...
(Date:2/28/2015)... MO (PRWEB) February 28, 2015 ... provider of outsourced sales, marketing and supply chain ... client, BIOTA Botanicals, is bringing its award winning ... worldwide, BIOTA Botanicals’ products are specifically created to ... care experts, BIOTA is committed to marrying science ...
Breaking Medicine News(10 mins):Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 2Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 3Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 4Health News:New Survey Reveals “Lack of Time” Is the Number #1 Barrier to Innovative Thinking 2Health News:New Survey Reveals “Lack of Time” Is the Number #1 Barrier to Innovative Thinking 3Health News:Atlantic NeuroSurgical Specialists (ANS) Focus on National Brain Injury Awareness Month to Educate the General Public on Head Trauma 2Health News:Atlantic NeuroSurgical Specialists (ANS) Focus on National Brain Injury Awareness Month to Educate the General Public on Head Trauma 3Health News:New Gene Therapy Procedure Could Hold Key to Preventing Blindness for Certain Patients 2Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 2Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 3
(Date:1/22/2015)... and Markets ( http://www.researchandmarkets.com/research/4trb7t/biometrics_a ) has announced the ... report to their offering. , The ... individual is who she/he is claiming to be, and for ... unique physical characteristics, such as fingerprint, hand or palm print, ...
(Date:1/22/2015)... , Jan. 13, 2015 /PRNewswire/ - Today, FindBiometrics, the leading source ... launch of its new website design. "When we ... infancy", says Peter O,Neill , founder and CEO of ... industry needs involvement from the key players on a very ...
(Date:1/22/2015)... 2015 Technology Showcase, Hall E -   EyeLock Inc. ... announced it will showcase its EyeLock ID technology integrated in ... of Energy,s Oak Ridge National Laboratory (ORNL) at ... iris identity authentication technology is being used to validate the ...
Breaking Biology News(10 mins):Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 3
Other Contents